Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy

Amanda M. Cotter, Kathleen F. Brookfield, Lunthita M. Duthely, Victor H. Gonzalez Quintero, Jonell E. Potter, Mary J. O'Sullivan

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Objective: The objective of the study was to determine whether the duration of membrane rupture of 4 or more hours is a significant risk factor for perinatal transmission of human immunodeficiency virus (HIV) in the era of combination antiretroviral therapy (ART). Study Design: This was a prospective cohort study of 717 HIV-infected pregnant women-infant pairs with a delivery viral load available who received prenatal care and delivered at our institution during the interval 1996-2008. Results: The cohort comprised 707 women receiving ART who delivered during this interval. The perinatal transmission rate was 1% in women with membranes ruptured for less than 4 hours and 1.9% when ruptured for 4 or more hours. For 493 women with a delivery viral load less than 1000 copies/mL receiving combination ART in pregnancy, there were no cases of perinatal transmission identified up to 25 hours of membrane rupture. Logistic regression demonstrated only a viral load above 10,000 copies/mL as an independent risk factor for perinatal transmission. Conclusion: Duration of membrane rupture of 4 or more hours is not a risk factor for perinatal transmission of HIV in women with a viral load less than 1000 copies/mL receiving combination ART.

Original languageEnglish (US)
Pages (from-to)482.e1-482.e5
JournalAmerican journal of obstetrics and gynecology
Volume207
Issue number6
DOIs
StatePublished - Dec 2012

Keywords

  • antiretroviral therapy
  • duration of membrane rupture
  • perinatal transmission
  • pregnancy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy'. Together they form a unique fingerprint.

  • Cite this